Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of beta-thalassemia/hemoglobin E patients
- PMID: 17617032
- DOI: 10.1515/CCLM.2007.145
Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of beta-thalassemia/hemoglobin E patients
Abstract
Background: Iron-induced oxidative stress may be implicated in the alteration of the lipoprotein-associated antioxidant enzymes paraoxonase 1 (PON1) and platelet-activating factor acetylhydrolase (PAF-AH), leading to atherosclerosis-related vascular complication in patients with beta-thalassemia hemoglobin E (beta-thal/Hb E).
Methods: Plasma and lipoprotein enzyme activities of PON1 and PAF-AH were studied in 13 mild to moderate and 15 severe cases of beta-thal/Hb E in comparison with 15 normal subjects.
Results: PON1 activity was significantly reduced in association with oxidative stress in the patients. There were significant correlations between high-density lipoprotein (HDL)-PON1 activity and oxidative stress markers, including plasma levels of alpha-tocopherol (r=0.694 p<0.001) and the ratio of cholesteryl linoleate to cholesteryl oleate (CL/CO, r=0.662, p<0.001) in HDL. On the other hand, PAF-AH activity was markedly increased in patients by approximately two-fold and three- to four-fold in plasma and lipoproteins, respectively. Significant correlations of low-density lipoprotein (LDL) and HDL-PAF-AH activity with plasma iron, alpha-tocopherol and the CL/CO ratio were also demonstrated.
Conclusions: We suggest that impairment of PON1 activity may be directly caused by oxidative damage, while increased PAF-AH activity possibly results from oxidative stress-induced inflammatory response in beta-thal/Hb E patients.
Similar articles
-
Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.Perit Dial Int. 2004 Nov-Dec;24(6):580-9. Perit Dial Int. 2004. PMID: 15559488
-
Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.Thyroid. 2005 May;15(5):455-60. doi: 10.1089/thy.2005.15.455. Thyroid. 2005. PMID: 15929667 Clinical Trial.
-
The reduction of cholesteryl linoleate in lipoproteins: an index of clinical severity in beta-thalassemia/Hb E.Clin Chem Lab Med. 2006;44(5):574-81. doi: 10.1515/CCLM.2006.093. Clin Chem Lab Med. 2006. PMID: 16681427
-
Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.Biochem Pharmacol. 2003 Dec 1;66(11):2069-73. doi: 10.1016/s0006-2952(03)00559-8. Biochem Pharmacol. 2003. PMID: 14609731 Review.
-
High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications.Shock. 2004 Mar;21(3):210-21. doi: 10.1097/01.shk.0000111661.09279.82. Shock. 2004. PMID: 14770033 Review.
Cited by
-
Oxidative modification and poor protective activity of HDL on LDL oxidation in thalassemia.Lipids. 2010 Jul;45(7):627-33. doi: 10.1007/s11745-010-3435-y. Epub 2010 Jun 9. Lipids. 2010. PMID: 20532993
-
Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia.J Lipid Res. 2010 Nov;51(11):3331-41. doi: 10.1194/jlr.M007229. Epub 2010 Jul 12. J Lipid Res. 2010. PMID: 20625038 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous